{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T00:22:17Z","timestamp":1773015737706,"version":"3.50.1"},"reference-count":49,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T00:00:00Z","timestamp":1741737600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIBAA 28720210100409"],"award-info":[{"award-number":["PIBAA 28720210100409"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002923","name":"Consejo Nacional de Investigaciones Cient\u00edficas y T\u00e9cnicas","doi-asserted-by":"publisher","award":["PIP 0792"],"award-info":[{"award-number":["PIP 0792"]}],"id":[{"id":"10.13039\/501100002923","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2018-1801"],"award-info":[{"award-number":["2018-1801"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2018-0585"],"award-info":[{"award-number":["2018-0585"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2018-01871"],"award-info":[{"award-number":["2018-01871"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003074","name":"Agencia Nacional de Promoci\u00f3n Cient\u00edfica y Tecnol\u00f3gica","doi-asserted-by":"publisher","award":["2019-02622"],"award-info":[{"award-number":["2019-02622"]}],"id":[{"id":"10.13039\/501100003074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Microbiol."],"abstract":"<jats:p>Chagas disease, caused by the parasite <jats:italic>Trypanosoma cruzi<\/jats:italic>, affects 6 million people worldwide. Although the drugs benznidazole (BZN) and nifurtimox are available to treat Chagas, they are not effective in the chronic phase when most patients are diagnosed. Moreover, long-term regimen and severe side effects often lead to poor adherence and treatment abandonment. These problems highlight the urgent need to develop new therapies to treat this neglected disease. Given that the antifungal drug nystatin (NYS) affects arginine uptake in yeasts, and fluctuations on arginine availability through transport processes in <jats:italic>T. cruzi<\/jats:italic> can negatively affect its viability, in this work we evaluated the potential of NYS for drug repurposing against <jats:italic>T. cruzi<\/jats:italic>. NYS inhibited arginine uptake and presented trypanocidal effect in both epimastigotes (IC50 0.17\u202f\u03bcM) and trypomastigotes (IC50 4.90\u202f\u03bcM). In addition, treatment of infected cells with NYS decreased the release of trypomastigotes with better efficacy than BZN (IC50s 4.83\u202f\u03bcM and 8.60\u202f\u03bcM, respectively) suggesting that NYS affects the progression of the intracellular life cycle. Furthermore, we observed a synergistic effect both in isolated trypomastigotes and infected cells when NYS was combined with BZN, which could enhance efficacy while improving treatment safety and adherence. As in yeasts, the mechanism of action of NYS in <jats:italic>T. cruzi<\/jats:italic> involved the plasma membrane disruption, and membrane transport processes, like amino acids and thymidine uptake, were affected prior to the disruption probably due to NYS interaction with the membrane. Drug repurposing is a recommended strategy by the World Health Organization to develop new therapeutic alternatives for neglected diseases. Our results indicate that NYS presents great potential to be repurposed as a trypanocidal drug to fight <jats:italic>T. cruzi<\/jats:italic>.<\/jats:p>","DOI":"10.3389\/fmicb.2025.1539629","type":"journal-article","created":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:06:19Z","timestamp":1741766779000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["The potential of the antifungal nystatin to be repurposed to fight the protozoan Trypanosoma cruzi"],"prefix":"10.3389","volume":"16","author":[{"given":"Bel\u00e9n Jes\u00fas","family":"Maciel","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chantal","family":"Reigada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fabio Augusto","family":"Digirolamo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"Rengifo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Claudio Alejandro","family":"Pereira","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mariana Rene\u00e9","family":"Miranda","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Melisa","family":"Say\u00e9","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2025,3,12]]},"reference":[{"key":"ref1","first-page":"246","article-title":"Leishmanicidal activity of nystatin (mycostatin): a potent polyene compound","volume":"47","author":"Ali","year":"1997","journal-title":"J. Pak. Med. Assoc."},{"key":"ref2","doi-asserted-by":"publisher","first-page":"95","DOI":"10.1016\/j.ijpddr.2014.02.002","article-title":"Drug repurposing and human parasitic protozoan diseases","volume":"4","author":"Andrews","year":"2014","journal-title":"Int. J. Parasitol. Drugs Drug Resist."},{"key":"ref3","doi-asserted-by":"publisher","first-page":"673","DOI":"10.1038\/nrd1468","article-title":"Drug repositioning: identifying and developing new uses for existing drugs","volume":"3","author":"Ashburn","year":"2004","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref4","doi-asserted-by":"publisher","first-page":"9014726","DOI":"10.1155\/2018\/9014726","article-title":"Pentavalent antimonials combined with other therapeutic alternatives for the treatment of cutaneous and mucocutaneous leishmaniasis: a systematic review","author":"Berbert","year":"2018","journal-title":"Dermatol. Res. Pract."},{"key":"ref5","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1016\/j.bbrc.2004.07.002","article-title":"Post genomic analysis of permeases from the amino acid\/auxin family in protozoan parasites","volume":"321","author":"Bouvier","year":"2004","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref6","first-page":"93","article-title":"Growth and differentiation in Trypanosoma cruzi. I. Origin of metacyclic trypanosomes in liquid media","volume":"6","author":"Camargo","year":"1964","journal-title":"Rev. Inst. Med. S\u00e3o Paulo"},{"key":"ref7","doi-asserted-by":"publisher","first-page":"2750","DOI":"10.1016\/j.bbagen.2018.08.015","article-title":"Cloning and characterisation of the equilibrative nucleoside transporter family of Trypanosoma cruzi: ultra-high affinity and selectivity to survive in the intracellular niche","volume":"1862","author":"Campagnaro","year":"2018","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref8","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1007\/BF00763064","article-title":"Intermediate metabolism in Trypanosoma cruzi","volume":"26","author":"Cazzulo","year":"1994","journal-title":"J. Bioenerg. Biomembr."},{"key":"ref9","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1016\/0022-5193(76)90169-7","article-title":"Derivation and properties of Michaelis\u2013Menten type and hill type equations for reference ligands","volume":"59","author":"Chou","year":"1976","journal-title":"J. Theor. Biol."},{"key":"ref10","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/0065-2571(84)90007-4","article-title":"Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors","volume":"22","author":"Chou","year":"1984","journal-title":"Adv. Enzym. Regul."},{"key":"ref11","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1242\/jcs.33.1.285","article-title":"The cell surface of Trypanosoma cruzi: cytochemistry and freeze-fracture","volume":"33","author":"De Souza","year":"1978","journal-title":"J. Cell Sci."},{"key":"ref12","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/0005-2736(81)90392-8","article-title":"Chemical composition of the plasma membrane from epimastigote forms of Trypanosoma cruzi","volume":"644","author":"Franco da Silveira","year":"1981","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref13","doi-asserted-by":"publisher","first-page":"115766","DOI":"10.1016\/j.bcp.2023.115766","article-title":"Identifying inhibitors of Trypanosoma cruzi nucleoside diphosphate kinase 1 as potential repurposed drugs for Chagas\u2019 disease","volume":"216","author":"Galceran","year":"2023","journal-title":"Biochem. Pharmacol."},{"key":"ref14","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1016\/j.ijbiomac.2016.12.065","article-title":"Identification of multi-targeted anti-migraine potential of nystatin and development of its brain targeted chitosan nanoformulation","volume":"96","author":"Girotra","year":"2017","journal-title":"Int. J. Biol. Macromol."},{"key":"ref15","doi-asserted-by":"publisher","first-page":"418","DOI":"10.1016\/j.bbamem.2018.11.006","article-title":"The pore-forming action of polyenes: from model membranes to living organisms","volume":"1861","author":"Kristanc","year":"2019","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"ref16","doi-asserted-by":"publisher","first-page":"106661","DOI":"10.1016\/j.actatropica.2022.106661","article-title":"Amphotericin B: a drug of choice for visceral leishmaniasis","volume":"235","author":"Kumari","year":"2022","journal-title":"Acta Trop."},{"key":"ref17","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1016\/S0166-6851(99)00129-2","article-title":"Sterol composition and biosynthesis in Trypanosoma cruzi amastigotes","volume":"104","author":"Liendo","year":"1999","journal-title":"Mol. Biochem. Parasitol."},{"key":"ref18","doi-asserted-by":"publisher","first-page":"e0168775","DOI":"10.1371\/journal.pone.0168775","article-title":"Arginine and lysine transporters are essential for Trypanosoma brucei","volume":"12","author":"Mathieu","year":"2017","journal-title":"PLoS One"},{"key":"ref19","doi-asserted-by":"publisher","first-page":"e32760","DOI":"10.1371\/journal.pone.0032760","article-title":"Cationic amino acid uptake constitutes a metabolic regulation mechanism and occurs in the flagellar pocket of Trypanosoma cruzi","volume":"7","author":"Miranda","year":"2012","journal-title":"PLoS One"},{"key":"ref20","doi-asserted-by":"publisher","first-page":"1899","DOI":"10.1056\/NEJMoa1313122","article-title":"Randomized trial of posaconazole and benznidazole for chronic Chagas\u2019 disease","volume":"370","author":"Molina","year":"2014","journal-title":"N. Engl. J. Med."},{"key":"ref21","doi-asserted-by":"publisher","first-page":"1295","DOI":"10.1056\/NEJMoa1507574","article-title":"Randomized trial of benznidazole for chronic Chagas\u2019 cardiomyopathy","volume":"373","author":"Morillo","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"ref22","doi-asserted-by":"publisher","first-page":"939","DOI":"10.1016\/j.jacc.2016.12.023","article-title":"Benznidazole and Posaconazole in eliminating parasites in asymptomatic T. cruzi carriers","volume":"69","author":"Morillo","year":"2017","journal-title":"J. Am. Coll. Cardiol."},{"key":"ref23","doi-asserted-by":"publisher","first-page":"46","DOI":"10.1016\/0014-5793(94)00730-6","article-title":"Nystatin changes the properties of transporters for arginine and sugars. An in vitro study","volume":"350","author":"Opekarov\u00e1","year":"1994","journal-title":"FEBS Lett."},{"key":"ref24","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1074\/jbc.275.2.1495","article-title":"Trypanosoma cruzi arginine kinase characterization and cloning. A novel energetic pathway in protozoan parasites","volume":"275","author":"Pereira","year":"2000","journal-title":"J. Biol. Chem."},{"key":"ref25","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/S1473-3099(23)00651-5","article-title":"Efficacy and safety of fexinidazole for treatment of chronic indeterminate Chagas disease (FEXI-12): a multicentre, randomised, double-blind, phase 2 trial","volume":"24","author":"Pinazo","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"ref26","doi-asserted-by":"publisher","first-page":"1233253","DOI":"10.3389\/fphar.2023.1233253","article-title":"Navigating drug repurposing for Chagas disease: advances, challenges, and opportunities","volume":"14","author":"Porta","year":"2023","journal-title":"Front. Pharmacol."},{"key":"ref27","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/S0140-6736(10)60061-X","article-title":"Chagas disease","volume":"375","author":"Rassi","year":"2010","journal-title":"Lancet"},{"key":"ref28","doi-asserted-by":"publisher","first-page":"105241","DOI":"10.1016\/j.jddst.2023.105241","article-title":"Trypanocidal activity of liposomal isotretinoin and loratadine formulations","volume":"91","author":"Reigada","year":"2024","journal-title":"J. Drug Deliv. Sci. Technol."},{"key":"ref29","doi-asserted-by":"publisher","first-page":"e01947","DOI":"10.1016\/j.heliyon.2019.e01947","article-title":"Repurposing terconazole as an anti Trypanosoma cruzi agent","volume":"5","author":"Reigada","year":"2019","journal-title":"Heliyon"},{"key":"ref30","doi-asserted-by":"publisher","first-page":"e0005472","DOI":"10.1371\/journal.pntd.0005472","article-title":"Trypanocidal effect of isotretinoin through the inhibition of polyamine and amino acid transporters in Trypanosoma cruzi","volume":"11","author":"Reigada","year":"2017","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref31","doi-asserted-by":"publisher","first-page":"106920","DOI":"10.1016\/j.actatropica.2023.106920","article-title":"Effectiveness of the repurposed drug isotretinoin in an experimental murine model of Chagas disease","volume":"2023","author":"Rial","year":"2023","journal-title":"Acta Trop."},{"key":"ref32","doi-asserted-by":"publisher","first-page":"2913","DOI":"10.1016\/j.bbagen.2017.08.015","article-title":"Evaluation of proline analogs as trypanocidal agents through the inhibition of a Trypanosoma cruzi proline transporter","volume":"1861","author":"Say\u00e9","year":"2017","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"ref33","doi-asserted-by":"publisher","first-page":"e0007481","DOI":"10.1371\/journal.pntd.0007481","article-title":"Crystal violet structural analogues identified by in silico drug repositioning present anti-Trypanosoma cruzi activity through inhibition of proline transporter TcAAAP069","volume":"14","author":"Say\u00e9","year":"2020","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref34","doi-asserted-by":"publisher","first-page":"31541","DOI":"10.1074\/jbc.M801367200","article-title":"A Trypanosoma cruzi phosphatidylinositol 3-kinase (TcVps34) is involved in osmoregulation and receptor-mediated endocytosis","volume":"283","author":"Schoijet","year":"2008","journal-title":"J. Biol. Chem."},{"key":"ref35","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1089\/aid.1993.9.475","article-title":"Inhibition of HIV-1 replication in H9 cells by nystatin-a compared with other antiviral agents","volume":"9","author":"Selvam","year":"1993","journal-title":"AIDS Res. Hum. Retrovir."},{"key":"ref36","doi-asserted-by":"publisher","first-page":"53","DOI":"10.2174\/1568005053174636","article-title":"Amino acid metabolic routes in Trypanosoma cruzi: possible therapeutic targets against Chagas\u2019 disease","volume":"5","author":"Silber","year":"2005","journal-title":"Curr. Drug Targets Infect. Disord."},{"key":"ref37","doi-asserted-by":"publisher","first-page":"114969","DOI":"10.1016\/j.addr.2023.114969","article-title":"Reviving the interest in the versatile drug nystatin: a multitude of strategies to increase its potential as an effective and safe antifungal agent","volume":"199","author":"Sousa","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"ref38","doi-asserted-by":"publisher","first-page":"397","DOI":"10.1139\/y63-048","article-title":"Amino acid transport in yeast and effects of nystatin","volume":"41","author":"Stachiewicz","year":"1963","journal-title":"Can. J. Biochem. Physiol."},{"key":"ref39","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.bbrc.2005.11.062","article-title":"The sterol-binding antibiotic nystatin inhibits entry of non-opsonized Leishmania donovani into macrophages","volume":"339","author":"Tewary","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref40","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1111\/j.1462-5822.2004.00397.x","article-title":"L-Proline is essential for the intracellular differentiation of Trypanosoma cruzi","volume":"6","author":"Tonelli","year":"2004","journal-title":"Cell. Microbiol."},{"key":"ref41","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/S1473-3099(17)30538-8","article-title":"Treatment of adult chronic indeterminate Chagas disease: proof-of-concept randomized placebo-controlled study of benznidazole and three E1224 dosing regimens","volume":"18","author":"Torrico","year":"2018","journal-title":"Lancet Infect. Dis."},{"key":"ref42","doi-asserted-by":"publisher","first-page":"e1186","DOI":"10.1093\/cid\/ciac579","article-title":"A phase 2, randomized, multicenter, placebo-controlled, proof-of-concept trial of oral fexinidazole in adults with chronic indeterminate Chagas disease","volume":"76","author":"Torrico","year":"2023","journal-title":"Clin. Infect. Dis."},{"key":"ref43","doi-asserted-by":"publisher","first-page":"31854","DOI":"10.26717\/BJSTR.2021.40.006392","article-title":"Repurposed nystatin to inhibit SARS-CoV-2 and mutants in the GI tract","volume":"40","author":"Vir\u00e1g","year":"2021","journal-title":"Biomed. J. Sci. Tech. Res."},{"key":"ref44","first-page":"1","volume-title":"Multidrug therapy against leprosy: development and implementation over the last 25 years","year":"2004"},{"key":"ref45","first-page":"33","article-title":"Chagas disease in Latin America: an epidemiological update based on 2010 estimates","volume":"90","year":"2015","journal-title":"Wkly. Epidemiol. Rec."},{"key":"ref46","volume-title":"The selection and use of essential medicines 2023. Executive Summary of the report of the 24th WHO Expert Committee on Selection and Use of Essential Medicines","year":"2023"},{"key":"ref47","doi-asserted-by":"publisher","first-page":"2338","DOI":"10.2174\/1568026619666181220114627","article-title":"Activity of fenticonazole, tioconazole and nystatin on new world Leishmania species","volume":"18","author":"Yamamoto","year":"2018","journal-title":"Curr. Top. Med. Chem."},{"key":"ref48","doi-asserted-by":"publisher","first-page":"e720","DOI":"10.1371\/journal.pntd.0000720","article-title":"NECT is next: implementing the new drug combination therapy for Trypanosoma brucei gambiense sleeping sickness","volume":"4","author":"Yun","year":"2010","journal-title":"PLoS Negl. Trop. Dis."},{"key":"ref49","doi-asserted-by":"publisher","first-page":"3963","DOI":"10.2174\/1381612827666210216152654","article-title":"Chagas disease chemotherapy: What do we know so far?","volume":"27","author":"Zuma","year":"2021","journal-title":"Curr. Pharm. Des."}],"container-title":["Frontiers in Microbiology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1539629\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,12]],"date-time":"2025-03-12T08:06:23Z","timestamp":1741766783000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmicb.2025.1539629\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,12]]},"references-count":49,"alternative-id":["10.3389\/fmicb.2025.1539629"],"URL":"https:\/\/doi.org\/10.3389\/fmicb.2025.1539629","relation":{},"ISSN":["1664-302X"],"issn-type":[{"value":"1664-302X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,12]]},"article-number":"1539629"}}